Bionest part of Accenture

Specialized services for rare diseases, gene therapy and precision medicine

The challenge

We bring life sciences to life

With our acquisition of Bionest, Accenture has expanded our capabilities for a transformative era of innovation in life sciences. Cell and gene therapies, advanced therapeutics, treatments in rare diseases, oncology, central nervous system (CNS) and autoimmune disorders are expanding amid evolving regulatory and pricing dynamics. We’re dedicated to delivering innovative solutions globally, helping clients navigate this landscape to develop successful commercial, medical and access strategies.

How we help

Advanced Therapeutics

We specialize in navigating the expanding and complex landscape of precision medicine and cell and gene therapies. Our strategies cover all aspects, from go-to-market to policy and advocacy.

Rare Disease

We provide strategic and scientifically informed understanding of rare disease indications before, during, and after launch.

Ex-US Go-to-Market

We guide biotech and pharma in crafting objective ex-US go-to-market (G2M) strategies, providing financial, strategic and operational alignment for successful execution.

Reinvention in action

1 1

Patient Support Program

New (Cell & Gene Therapy) CGT, with a “CAR-T like” patient journey sought to support stakeholders and differentiate vs. future competitors. We mapped impactful Patient Support Program (PSP) solutions tailored to market requirements.

EU Advocacy Strategy for Gene Therapy

A US-based biotech developing a high cluster of orthologous groups(high-COGS) GxTx engaged us to develop a two-year cross-functional plan to shape the EU payer and political landscape.

Biomarker Market Access Playbook

We helped a pharmaceutical giant develop a global framework for CDx development and pre-launch planning. Our playbook offers clear guidance and links key questions with activities, facilitating better planning and milestone anticipation.

EU Market Entry & Mapping in an Orphan CNS Disease

For a US biotech exploring EU market entry in an orphan CNS disease, we developed a revenue forecast and recommended a go-direct G2M model.